Novavax Announces Closing of Public Offering
16 Abril 2018 - 5:05PM
GAITHERSBURG, Md., April 16, 2018
(GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage
biotechnology company committed to delivering novel products to
prevent infectious diseases, today announced the closing of the
underwritten public offering priced on Wednesday, April 11,
2018.
The company issued 34,848,507
shares of its common stock, including 4,545,457 shares pursuant to
the underwriters' option to purchase additional shares. The shares
were issued at $1.65 per share resulting in total gross proceeds
from this offering of $57.5 million before deducting the
underwriters discount and offering expenses.
Net proceeds from the offering are
to be used for general corporate purposes, including but not
limited to working capital, capital expenditures, research and
development expenditures related to clinical and preclinical
vaccine candidates, clinical trial expenditures, as well as
acquisitions and other strategic purposes.
Citigroup and Piper Jaffray &
Co. acted as joint book-running managers of the offering. Cantor
Fitzgerald & Co. also acted as a book-running manager.
Ladenburg Thalmann and B. Riley FBR acted as co-managers.
The shares described above were
issued pursuant to a final prospectus supplement and accompanying
prospectus. The company filed the final prospectus supplement
relating to the offering with the Securities and Exchange
Commission ("SEC") on April 13, 2018, which is available along with
the accompanying prospectus filed with the SEC in connection with
the company's shelf registration statement on Form S-3, previously
declared effective by the SEC, on the SEC's website at www.sec.gov.
This press release does not and shall not constitute an offer to
sell or the solicitation of an offer to buy, nor will there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction. Copies of the final prospectus supplement and the
accompanying prospectus may be obtained from Citigroup and Piper
Jaffray & Co., Attention: Citigroup, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at (800) 831-9146; or Piper Jaffray & Co., Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN
55402, by telephone at (800) 747-3924 or by email at
prospectus@pjc.com.
About
Novavax
Novavax, Inc. (Nasdaq:NVAX) is a
clinical-stage biotechnology company committed to delivering novel
products to prevent infectious diseases. Its RSV and influenza
nanoparticle vaccine candidates are Novavax' most advanced
clinical programs and are at the forefront of Novavax' efforts to
improve global health.
Forward-Looking Statements
Statements
contained in this release using words such as "expects" and
"intends" are forward-looking statements that involve a number of
risks and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements. These
risks and uncertainties include, but are not limited to: the
possible adverse impact on the market price of our shares of common
stock due to the dilutive effect of the securities sold in the
offering; our planned use of the proceeds from this offering;
capital market risks; our ability to raise additional capital when
needed; and other risk factors identified from time to time in the
reports we file with the SEC, including our Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on
Form 8-K, which are available at www.sec.gov. We caution investors
not to place considerable reliance on the forward-looking
statements contained in this press release. You are encouraged to
read our filings with the SEC, available at sec.gov, for a
discussion of these and other risks and uncertainties. The
forward-looking statements in this press release speak only as of
the date of this document, and we undertake no obligation to update
or revise any of the statements. Our business is subject to
substantial risks and uncertainties, including those referenced
above. Investors, potential investors and others should give
careful consideration to these risks and uncertainties.
Contact:
Investors:
Erika Trahan
Senior Manager, Investor & Public Relations
ir@novavax.com
240-268-2000
Westwicke Partners
John Woolford
John.woolford@westwicke.com
443-213-0506
Media:
Sam Brown
Mike Beyer
mikebeyer@sambrown.com
312-961-2502
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novavax, Inc. via Globenewswire
Novavax (NASDAQ:NVAX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novavax (NASDAQ:NVAX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024